Mantle Cell Lymphoma

Pirtobrutinib receives accelerated FDA approval for the treatment of R/R mantle cell lymphoma

The Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib for the treatment of relapsed/refractory (R/R) mantle cell lymphoma…

ASH press briefing rundown: changing the status quo for blood cancers

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

EHA 2021: key highlights in lymphoid malignancies

The 26th Congress of the European Hematology Association (EHA) 2021, which was held virtually from 9-17 of June, 2021, offered…

Non-covalent BTK inhibitor LOXO-305 shows promising results in advanced B-cell malignancies

Bruton’s tyrosine kinase (BTK) plays an essential role in the B-cell antigen receptor signaling pathway and is required for the…

The Transplant Sessions: post-ASH 2020 roundtable discussion

A session with experts Bruce Levine and Christian Chabannon, who discuss the exciting updates in transplantation and cell therapy from…

FDA approves brexucabtagene autoleucel for MCL

The Food and Drug Administration (FDA) has approved a new path of treatment for patients with mantle cell lymphoma (MCL)…

The REAL classification of lymphoma

Twenty-five years ago, almost to the day, there was a paradigm shift in the classification of lymphoma.

features: Mantle Cell Lymphoma